The global synthetic biology market size was reached at USD 16.81 billion in 2024 and is expected to surpass around USD 58.23 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 13.22% during the forecast period 2025 to 2034. The U.S. synthetic biology market size was estimated at USD 5.24 billion in 2024. The synthetic biology market is expanding rapidly due to advancements in genetic engineering and increasing demand for sustainable solutions. Innovations in CRISPR gene-editing technology, synthetic DNA synthesis, and AI-driven bioengineering are fueling industry growth.
Governments and private sectors are investing heavily in research, further accelerating developments in healthcare, biofuels, and industrial biotechnology. Additionally, growing awareness of sustainable alternatives in food production, such as lab-grown meat and plant-based proteins, is driving adoption. The pharmaceutical sector is leveraging synthetic biology for vaccine development and gene therapies. As industries recognize the potential of engineered organisms, synthetic biology is expected to revolutionize multiple sectors, making it a crucial player in the future of biotechnology.
What is a Synthetic Biology?
Synthetic biology is an advanced field of science that combines biology, engineering, and computer science to design and build new biological systems. Scientists modify or create DNA sequences to develop organisms with specific traits, such as bacteria that produce biofuels or crops with improved resistance to pests. This approach enables innovations in medicine, agriculture, and environmental conservation. One key application is in healthcare, where synthetic biology helps in developing personalized medicine and synthetic insulin. In agriculture, it enhances crop yields and reduces the need for chemical fertilizers. Additionally, synthetic biology is used to create biodegradable plastics, reducing environmental pollution. This field continues to evolve, unlocking solutions for global challenges like climate change, food security, and disease prevention.
Key insights beneficial to the synthetic biology market:
Report Scope
Area of Focus | Details |
Market Size in 2025 | USD 19.03 Billion |
Expected Market Size in 2034 | USD 58.23 Billion |
CAGR 2025 to 2034 | 13.22% |
Prime Region | North America |
High Growth Region | Asia-Pacific |
Key Segments | Product, Technology, Application, End User, Region |
Key Companies | Thermo Fisher Scientific, Inc., Synthetic Genomics Inc., Synthego, Scarab Genomics, Llc, Pareto Bio, Inc., Novozymes, New England Biolabs, Merck Kgaa (Sigma-Aldrich Co. Llc), Illumina, Inc., Eurofins Scientific, Enbiotix, Inc., Creative Enzymes., Creative Biogene., Codexis, Inc., Bota Biosciences Inc. |
Expanding Synthetic Food Production
Reduction in DNA Sequencing and Synthetic Costs
Ethical Concerns and Public Perception
Regulatory and Safety Challenges
Rapid Growth in the Biotechnology Sector
Adoption in the Cosmetics Industry
Excessive Costs for Research and Development
Potential Threats to the Environment
The synthetic biology market is segmented into product, technology, application, end user, and region. Based on product, the market is classified into oligonucleotide/oligo pools and synthetic DNA, chassis organism, enzymes, xeno-nucleic acids, and cloning technologies kits. Based on technology, the market is classified into NGS technology, PCR technology, genome editing technology, bioprocessing technology, microfluidics, bioinformatics, nanotechnology, and other. Based on application, the market is classified into healthcare and non-healthcare. Based on end use, the market is classified into biotechnology and pharmaceutical companies, academic and research institutes and others.
Oligonucleotide/Oligo Pools and synthetic DNA: This segment has dominated the market in 2024 (35.47%). Oligonucleotide and synthetic DNA products are crucial factors in the synthetic biology market. These small deoxyribonucleotide or ribonucleotide sequences are made to order for purposes of gene therapy, diagnostic tools and even for carrying out synthetic biology experiments. Oligo pools allow for the synthesis of thousands of varying sequences at once thus promoting high throughput screening and functional genomics. Complete genes or synthetic DNA structures that may include genetic pathways are essential in the creation of modified organisms for use in Industry, Agriculture and medicine.
Enzymes: Enzymes are very important when it comes to synthetic biology and act as biocatalysts for several biochemical activities that are needed for the process. They assist in processes such as synthesis, degradation, and alteration of DNA thus enabling the precise design of various genes. Enzymes like polymerase, ligase and harmful nucleases are of great relevance in gene editing, gene cloning procedures and also in metabolic engineering activities.
Chassis Organisms: Chassis organisms are host cells that are constructed like Escherichia coli, yeast, or algae and are used in turn for the development of synthetic biology. These organelles are engineered in particular to produce certain products, where biofuels and bioplastics lie within the parenthesis of drugs and food additives. Because of their potential to accommodate synthetic pathways with the optimization of metabolic processes, they are considered the backbone of the bio-manufacturing sector.
Xeno-Nucleic Acids(XNAs): Synthetic nucleic acid for stable DNA and RNA. Xeno-nucleic acids (XNAs) are similar to natural DNA or RNA but are conformed in a manner that they are more chemically stable and do not undergo any enzymatic degradation. In contrast to the natural nucleic acid XXX, made up of stable XNAs, it is possible to use XNAs in medicines and in making Xeno that contain the XX nucleic acid structures. They are also being developed for gene therapy instead of the standard nucleic acids and for designing new biopolymers as molecular machinery.
Cloning Technologies Kits: The cloning technologies kits segment is expected to witness the fastest CAGR during the forecast period. With the onset of synthetic biology, the core methodology of adding genetic material to organizing systems has received a lot of focus and cloning technologies kits have made it possible to develop and commercialize this process with ease. This kit helps the users with the reagents, tools and protocols to design the alteration of genes and design biological apparatus ready for use. They are essential in the production of therapeutic proteins and biomaterial development technologies.
NGS Technology: Synthetic biology involves next-generation sequencing (NGS) technologies which form the basis of the control of biological functions in synthetic biology due to their ability to analyze the genomes significantly faster. It facilitates the plasmid structure sequencing as well as genomes of interest over a certain population, which includes, for instance, sequencing of metagenomes. NGS not only aids in the design of synthetic pathways and the construction of organisms but also assists in the streamlining of genetic circuits.
PCR Technology: Polymerase chain reaction (PCR) technology is one of the most significant aspects of synthetic biology since it allows the multiplication of a specified DNA sequence that can be used for various purposes. When cloning, analyzing gene expression, or producing artificial assemblages, PCR is also necessary. PCR is the technique that is utilized when high sensitivity and accuracy are needed as in genetic diagnostics and genetic manipulation with the help of; qPCR or quantitative polymerase chain reaction and digital PCR.
Bioprocessing Technology: Every innovation in synthetic biology must eventually integrate into an industrial-scale biomanufacturing system and that is where bioprocessing technologies come into play. It includes activities such as growing genetically engineered organisms and harvesting products derived from biological sources for instance biofuels, bioplastics and therapeutics. With modern bioprocessing techniques such as fermentation optimization and downstream processing, it is possible to obtain products that have high yield and purity.
Genome Editing Technology: The development of genome editing tools CRISPR-Cas9, TALENs, and ZFNs, has had a very positive impact on the field of synthetic biology in that it has become possible to modify specific sites within a genetic material. These instruments enables the scientists to edit, delete or add DNA in the creation of an organism with a specifically designed trait. Improvement of the genome editing has led to the development of the gene therapy, enhancement of crops, and enhancement of the microbial production systems.
Healthcare: The application is revolutionizing the healthcare landscape with its potential in gene therapy, personalized medication, and vaccine manufacture. New genetically engineered vectors and genetic based systems are developed to treat genetic diseases, tumors, or infectious pathogens. Other techniques aimed at the treatment and prevention of a disease include CRISPR gene editing and synthetic biology applications such as targeted therapy and diagnostics development.
Synthetic Biology Market Revenue Share, By Application, 2024 (%)
Application | Revenue Share, 2024 (%) |
Healthcare | 56.97% |
Non-Healthcare | 43.03% |
Non-Healthcare: In addition to healthcare, synthetic biology is changing the game for other sectors like agriculture, energy and materials. For agriculture, this helps in developing crops through genetic means with better yield, resist pest attacks and better nutrient usage. For biobased energy, synthetic biology is the application of modified microbes for producing fuels such as biofuels than using the traditional way of fossil fuels.
The North America synthetic biology market size was estimated at USD 6.99 billion in 2024 and is expected to reach around USD 24.21 billion by 2034. The region dominates the market thanks to a high level of R&D expenditure, development of relevant infrastructure, and existence of a thriving biotechnology market. Within this region, the U.S. holds the highest rank owing to its innovations in health care, agricultural biotechnology, and industrial bio-manufacturing.
The Europe synthetic biology market size was accounted for USD 4.63 billion in 2024 and is projected to hit around USD 16.02 billion by 2034. Europe is also a major region, standing out from others with a range of supportive policies and funding opportunities such as Horizon Europe. It strives for this goal while promoting bio-based materials and bioenergy, which are more sustainable. Germany, the UK, and France are prominent players in the industrial biotechnology area, where developments concerning healthcare sectors such as gene therapy and synthetic vaccines are becoming more prevalent.
The Asia-Pacific synthetic biology market size was exhibited at USD 4.05 billion in 2024 and is predicted to surpass around USD 14.03 billion by 2034. Asia-Pacific market is expected to grow owing to the rapid expansion in the investments related to the biotechnology sector and the rising demand for the eco-friendly options. Further, countries such as China, India, and Japan are implementing agricultural, health and energy-related biotechnology and synthetic biology strategies. State administration encourages such initiatives while academic institutions enter into active cooperation with businesses, which enables the growth of the region.
Synthetic Biology Market Revenue Share, By Region, 2024 (%)
Region | Revenue Share, 2024 (%) |
North America | 41.58% |
Europe | 27.52% |
Asia-Pacific | 24.10% |
LAMEA | 6.80% |
The LAMEA synthetic biology market was valued at USD 1.14 billion in 2024 and is anticipated to reach around USD 3.96 billion by 2034. Latin America, the Middle East, and Africa (LAMEA) are areas where the relatively new field of synthetic biology is gaining ground with the primary emphasis being on biofuels and sustainable agriculture. While Brazil and Argentina have sought to enhance the agricultural biotechnology for higher crop yields, countries in the Middle East are latching onto biomaterials for renewable energy. The lack of adequate infrastructure and financing remains an impediment. However, capacity building initiatives and partnerships among nations are slowly increasing the development of the market in these regions.
The new players in the synthetic biology industry are causing technological leaps due to their opportunities of focused application and advanced technologies. Newer and smaller firms are working towards the provision of the specific application like that of the provision of alternative proteins, precision gene therapies and bio plastics. Many of the players are also using CRISPR and AI, and automation to carry out genetic engineering more efficiently and cheaply than before. They often work with universities and big biotech companies who have resources to help in product development. Besides that, the new players are also tackling the issues of sustainability by coming up with environmental friendly solutions such as biodegradable plastics and biofuel.
Market Segmentation
By Product
By Technology
By Application
By End Use
By Region